{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:45:10Z","timestamp":1792683910652,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021524","name":"School of Life Sciences and Biotechnology Division of Life Sciences, Korea University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008866","name":"Changhai Hospital of Shanghai","doi-asserted-by":"publisher","award":["2024LYB02"],"award-info":[{"award-number":["2024LYB02"]}],"id":[{"id":"10.13039\/501100008866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymthe.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:56:03Z","timestamp":1754751363000},"page":"5516-5529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"Weijia","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7319-3657","authenticated-orcid":false,"given":"Ruidong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.014_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.014_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051075","article-title":"Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.014_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.08.014_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.08.014_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1777064","article-title":"Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors","volume":"9","author":"Alcantara","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.08.014_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.014_bib7","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.014_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1172\/JCI0213853","article-title":"Thymocyte emigration is mediated by active movement away from stroma-derived factors","volume":"109","author":"Poznansky","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.014_bib9","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.014_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.014_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.014_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint Blockade Reverses Anergy in IL-13Ralpha2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.08.014_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2025.08.014_bib14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.08.014_bib15","article-title":"Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors","volume":"14","author":"Menz","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.014_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000518107","article-title":"Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article","volume":"44","author":"Siebenhuner","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ymthe.2025.08.014_bib17","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.014_bib18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.08.014_bib19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.014_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","article-title":"Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?","volume":"39","author":"Gires","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2025.08.014_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3243","article-title":"Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study","volume":"14","author":"Muller","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2025.08.014_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.seminoncol.2016.06.004","article-title":"Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells","volume":"43","author":"Wang","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.014_bib23","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1021\/acs.molpharmaceut.9b00185","article-title":"Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application","volume":"16","author":"Ma","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2025.08.014_bib24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/jcm9061894","article-title":"CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer","volume":"9","author":"Bebnowska","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.08.014_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40164-022-00352-4","article-title":"Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside","volume":"11","author":"Liu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.014_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.08.014_bib29","article-title":"EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers","author":"Fang","year":"2022","journal-title":"ESMO Congress"},{"key":"10.1016\/j.ymthe.2025.08.014_bib27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","article-title":"A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3","volume":"75","author":"Mau-Sorensen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.08.014_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:27:20Z","timestamp":1779524840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625006446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525001625006446"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.014","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}